There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Catalent Inc. (CTLT) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$4.64, or -5.32%, to $82.51. Volume reached 48,410 shares, with price reaching a high of $83.15 and a low of $83.15. The stock was recently discussed on Yahoo Finance as it revealed that Catalent, Inc. to Present at September Investor Conferences.
As a NYSE listed company, CTLT falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $83.15 and fluctuated between $87.74 as its day high and $83.10 as its day low. The current market capitalization of Catalent Inc. is $14.84B. A total of 1.47 million shares were traded on the day, compared to an average of 1.15M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CTLT has seen 15 BUY and 17 SELL insider trades, representing the acquisition of 84,029 and the disposition of 21,007 shares. Over the last 12 months, there were 48 BUYs and 50 SELLs from insiders. Insiders purchased 8,057,245 shares during that period but sold 3,741,319.
In the most recent transaction, Hopson Ricky sold 2,216 shares of CTLT for 89.59 per share on Aug 31. After the transaction, the Pres. Clinical Dev Supply Div now owns 17,095 company shares. In a previous transaction on Aug 26, Gunther Scott sold 1,639 shares at 104.07 per share. CTLT shares that SVP, Quality & Reg. Affairs owns now total 23,988.
Among the insiders who sold shares, Riley Michael A. disposed of 2,491 shares on Aug 26 at a per-share price of $104.07. This resulted in the Pres. Bio Product Delivery Div holding 6,592 shares of CTLT after the transaction. In another insider transaction, Riley Michael A. sold 1,482 shares at $103.04 per share on Aug 25. Company shares held by the Pres. Bio Product Delivery Div now total 9,083.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CTLT in the last 3 months, the mean price target is $123.75 with high estimates of $145.00 and low estimates of $105.00. In terms of 52-week highs and lows, CTLT has a high of $142.09 and a low of $86.11.
As of this writing, CTLT has an earnings estimate of $0.58 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.7 per share and a lower estimate of $0.46. The company reported an EPS of $1.12 in the last quarter, which was 1.82% higher than expectations of $1.1.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 15 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTLT is Underweight with a score of 4.60. A total of 10 analysts rated the stock as Buy while 3 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.